166 related articles for article (PubMed ID: 22072801)
1. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Hu-Lowe D; Brega N; Patyna S
Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
[No Abstract] [Full Text] [Related]
2. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
3. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Christensen JG
Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
[TBL] [Abstract][Full Text] [Related]
4. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Di Lorenzo L
J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
[No Abstract] [Full Text] [Related]
6. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
7. Canertinib pfizer.
Galmarini CM
IDrugs; 2004 Jan; 7(1):58-63. PubMed ID: 14730468
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
9. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
10. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
12. Multitarget tyrosine kinase inhibition: [and the winner is...].
Verweij J; de Jonge M
J Clin Oncol; 2007 Jun; 25(17):2340-2. PubMed ID: 17557945
[No Abstract] [Full Text] [Related]
13. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase inhibitors: novel tools in cancer therapy.
Marmé D
Urologe A; 2004 Sep; 43 Suppl 3():S148. PubMed ID: 15148578
[No Abstract] [Full Text] [Related]
15. Cancer and kinases: reports from the front line.
Burley SK
Genome Biol; 2006; 7(4):314. PubMed ID: 16677415
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
17. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
18. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
19. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy and new anticancer drugs in advanced disease.
Silva S; Danson S
Thorac Surg Clin; 2013 Aug; 23(3):411-9. PubMed ID: 23931023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
